Closing out my presidential year

Looking back on some of the highlights of another great year for the College

As I close out my presidential year, it's my pleasure to look back on some of the highlights of 2023 – another great year for the College.

Membership continues to grow, and it is gratifying to hear that the College is meeting your needs. According to our most recent survey, some of the most popular reasons why you value your membership include staying up to date with the latest developments in our specialty, interacting and networking with colleagues, having access to free educational, clinical and practice management resources, benefiting from advocacy efforts, and being a part of advancing the specialty.

In line with the continued strategic priorities under Vision Forward, we have continued to add to our practice management and educational resources this year. Just a few recent highlights:

- Our exclusive, easy-to-read summary of the new USP 797 Allergen Extract Exception that became effective Nov. 1.
- New AllergyTalk episodes, plus 20 new MicroCME topics, including “Biologics in Food Allergy” and “EDE: What to Do and What Not to Do.”
- It also has been a busy year for clinical guidance. In 2023, College committees and leadership collaborated with other organizations to publish a Practice Parameter on drug allergy and a GRADE guideline on chronic sinusitis. There are many more guidance documents in the development or review stage. I thank all of you who have taken the time to review and comment on these, prior to publication.
- And we've had numerous advocacy wins this year, both for physicians and patients. Our main areas of focus in 2023 included:
  - Preventing Medicare cuts.
  - Standardizing the prior authorization process.
  - Reducing “Good Faith Estimate” burdens.
- As always, the College helps keep our patients and the public educated about allergic diseases including asthma. Fresh web content, updated online patient brochures and videos, and dozens of media stories each month help us to accomplish this. And in 2023, we kept our successful “Time for an Allergist” digital campaign going strong, targeting primary care physicians and the public. This campaign has now reached millions of people, many of whom are searching for care physicians and the public. This campaign has now reached millions of people, many of whom are searching for allergists, and the knowledge that not all physicians have access to allergy-immunology education during their training. You can learn more at our CAPE symposium Sunday morning!
- In closing, the College continues to implement tactics identified under our Vision Forward strategic plan, and we have worked in recent months to identify strategies for 2024 and beyond. As the word “vision” implies, the leadership of the College plans with an eye to the immediate future as well as to address the longer-term challenges and changes we foresee. We must all continue to adapt for the benefit of our patients and our specialty. I am gratified to leave the College in such a strong, forward-focused place nearing the end of my term, and am humbled by the tremendous service of so many members and staff in the service of our specialty! And thank you for the honor of allowing me to serve as your president this past year.

Kathleen R. May, MD, FACAAI
ACAAI President

The easiest way to stay up to date

Use the meeting app to easily navigate the Annual Meeting

Keep track of symposia, abstracts, social events and more during the Annual Meeting with our mobile app. Download the app to access the full educational program, navigate the meeting with helpful maps, get local information and more.

Want to use more features? When you log in, you’ll be able to create your own schedule for the meeting and participate in the Passport Contest. To log in, use the email address you used to register for the Annual Meeting.

Download the app by searching for “ACAAI” in the app store and on Google Play, or visit annualmeeting.acaai.org.

The mobile app is sponsored by Sanofi & Regeneron.

You’re Invited | PRODUCT THEATER (non-CME) sponsored by ADMA Biologics

Join us live for our program
“Challenges Associated With Respiratory Infections in Patients With Primary Immune Deficiency. An Expert Discussion & Real-World Experience”

Saturday, November 11, 2023 • 11:35 AM to 1:00 PM PT
Anaheim Convention Center, 800 W Katella Avenue
Anaheim, CA 92802 | Product Theater 1

The Product Theater content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.

Dareen Siri, MD
Midwest Allergy Sinus Asthma

Scan to Register

bit.ly/acaai2023

Presenters

Dareen Siri, MD
Midwest Allergy Sinus Asthma

admbiologics.com
Leading a new age of plasma-derived products with proven immunotechnology

Discover our proven immunotechnology. ADMA has forged a new path forward in improving the lives of the immune compromised and other patients at risk for certain infections.

Visit the ASCENIV and BIVIGAM websites to see Full Prescribing Information, including BOXED WARNING.
Start your Saturday with something presidential

T

there is a lot to experience in
Anaheim and so much to do at
the Annual Meeting. What should
you add to your schedule? The Saturday
Presidential Plenary.

Start your Saturday with the Opening
Ceremony from 7:30 to 8:00 am in the
convention center’s Ballroom B-E. College
President Kathleen R. May, MD, FACAAI, will welcome you to the meeting and
discuss the current state of the College.
Also hear from Annual Meeting Program
Chair Jay A. Lieberman, MD, FACAAI, and Mrs. Debra R. Mahr, Alliance
Committee Chair.

Dr. May will also present the Gold
Headed Cane Award to Gary N. Gross,
MD, FACAAI. Dr. Gross has been a
College Fellow for 37 years.

Following the meeting’s Opening
Ceremony, stay for the Presidential
Plenary “Trending Topics in Allergy and
Immunology,” covering timely subjects in
A/I today:

• FDA Labeling Changes: Food
Allergens for Skin Testing
Jay E. Slater, MD

• Where Does ICS-SABA Fit in Asthma
Management?
Leonard B. Bacharier, MD, FACAAI

• Evolution in Anaphylaxis
David B. K. Golden, MD, FACAAI

• Bela Schick Lecture: Life is Too Short
to Drink Bad Wine
David R. Stukus, MD, FACAAI

The annual Bela Schick lecture is
named in honor of one of medicine’s
most respected scientists. Bela Schick
was born in Hungary, emigrated to the
U.S. in 1923, and was a pediatrician at Mt. Sinai in New York for many years.
He is best known for his work with
Clemens von Pirquet on anaphylaxis
and for the test he developed to assess
immunity to diphtheria.

Make time to attend plenaries
Sunday and Monday

In addition to Saturday’s Presidential Plenary
on A/I’s trending topics, you’ll want to attend
plenaries on Sunday and Monday too. Plenaries
are held in the convention center’s Ballroom B-E.

The Buzz on Biologics: To Asthma and Beyond

Speakers will provide current clinical data on biologics for conditions allergists/
immunologists treat on a regular basis. Attend on Sunday, Nov. 12 at 8:00 am in
Ballroom B-E in the convention center.

• Edward J. O’Connell Lecture

Biologics for Asthma: 20 Years Since the First
Approval and Where We Are Headed in 20 Years
John J. Oppenheimer, MD, FACAAI

The annual Edward J. O’Connell Lecture Award honors
the legacy of Dr. O’Connell, a past president of the College
(1990-1991), who was a caring, compassionate physician
with a lifelong passion for serving children. He was an
adept educator and authored nearly 100 original articles,
along with many book chapters related to allergy and
immunology.

• Biologics for Allergic Skin Conditions – When and for Whom?
Peck Y. Ong, MD, FACAAI

• Biologics for Food Allergies – On the Precipice of a New Era?
Brian P. Vickery, MD

Don’t Be Scared of the Skin: Practical
Pearls to Treat Urticaria and Atopic
Dermatitis

Get updates from the most recent
guidelines and practice parameters
related to allergic dermatologic
diseases on Monday, Nov. 13 at
8:00 am in Ballroom B-E in the
convention center.

• Updates on Urticaria
Jonathan A. Bernstein, MD,
FACAAI

• Managing Type 3 Angioedema
Marc A. Rodd, MD, MS

• Updates in Therapeutic Strategies for
Atopic Dermatitis
Mark Boguniewicz, MD, FACAAI

Keep up with the latest research

Explore the latest A/I research with ePosters
and author presentations

Attend engaging, interactive
visual presentations of the latest
research.

Visit Exhibit Hall C in the convention
center where authors will discuss their research in 10- to 15-minute slots.

Meet the Authors
Presentation Schedule

• Friday Nov. 10: 3:00 – 6:00 pm
• Saturday Nov. 11: 11:35 am – 1:00 pm
• Sunday Nov. 12: 11:35 am – 1:00 pm

When presentations are not being
made, self-service monitors will be
available for viewing ePosters.

The ePosters are interactive, easy to
read and searchable by topic, author
and title.

Don’t miss this year’s Late-breaking
Abstracts. See the latest clinical research
as authors deliver presentations on stage
in the ePoster area on Saturday during the
morning and afternoon session breaks
(9:35 – 10:00 am and 2:35 – 3:00 pm).

The presentations will be simulcast on
multiple ePoster monitors to maximize
viewing opportunities.

Plan to attend our oral abstracts
sessions on Saturday from 4:30 to 5:30 pm
in rooms 213AB, 213CD and 204B in the
convention center. Distinguished Industry
Oral Abstracts will also take place on
Saturday from 4:30 to 5:30 pm in rooms
210AB, 210CD.

You can also explore all ePosters 24/7
on the Annual Meeting app and online at
epostersonline.com/acaai2023/
now
and for several months after the meeting.

All abstracts selected for presentation
are published in the special Annals
of Asthma, Allergy and Immunology
supplement available at registration.
Frequent infections, allergy, and asthma may indicate underlying primary immunodeficiency (PI). Join Drs Jolan Walter and Nicholas Hartog for a discussion about how a PI called APDS may present in your practice, clinical data on the first and only FDA-approved treatment, Joenja® (leniolisib), and resources for testing for APDS and prescribing Joenja.

**DISCUSSION TOPICS**
- Recognizing APDS and Discussing and Identifying Resources and Access
- Joenja Clinical Trial Results
- Interactive Panel Discussion

**SPEAKER INFORMATION**

**Jolan E. Walter, MD**
University of South Florida and John Hopkins All Children's Hospital
St Petersburg, FL
Allergist and Immunologist

**Dr Nicholas Hartog, MD**
Helen DeVos Children's Hospital and Corewell Health West Medical Group
Grand Rapids, MI
Allergist and Immunologist

**INDICATIONS AND USAGE**
JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

**IMPORTANT SAFETY INFORMATION**
Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA. JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA. Live, attenuated vaccinations may be less effective if administered during JOENJA treatment. Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

The most common adverse reactions (incidence >10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis. Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA, please read the full Prescribing Information or go to www.JOENJA.com.
Frequent infections, allergy, and asthma may indicate underlying primary immunodeficiency (PI). Join Drs Jolan Walter and Nicholas Hartog for a discussion about how a PI called APDS may present in your practice, clinical data on the first and only FDA-approved treatment, Joenja® (leniolisib), and resources for testing for APDS and prescribing Joenja.

Product Theater 3 in Exhibit Hall C
Anaheim Convention Center
November 11, 2023
9:35 AM – 10:00 AM PT

INDICATIONS AND USAGE
JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION
Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA. JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA. Live, attenuated vaccinations may be less effective if administered during JOENJA treatment. Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

The most common adverse reactions (incidence >10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis. Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA, please read the full Prescribing Information or go to www.JOENJA.com.
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Commercial</td>
<td>435</td>
</tr>
<tr>
<td>AbbVie</td>
<td>726</td>
</tr>
<tr>
<td>Adma USA</td>
<td>632</td>
</tr>
<tr>
<td>ADMA Biologics</td>
<td>664</td>
</tr>
<tr>
<td>Advanced Infusion Care</td>
<td>337</td>
</tr>
<tr>
<td>ALK-Abelló, Inc.</td>
<td>627</td>
</tr>
<tr>
<td>Allergy &amp; Asthma Network</td>
<td>332</td>
</tr>
<tr>
<td>Allergy &amp; Asthma Proceedings</td>
<td>634</td>
</tr>
<tr>
<td>Allergy &amp; ENT Associates</td>
<td>545</td>
</tr>
<tr>
<td>Allergy Partners</td>
<td>443</td>
</tr>
<tr>
<td>AllergyEHR</td>
<td>426</td>
</tr>
<tr>
<td>AllerVie Health</td>
<td>424</td>
</tr>
<tr>
<td>Altus Biologics</td>
<td>636</td>
</tr>
<tr>
<td>Aluna</td>
<td>734</td>
</tr>
<tr>
<td>American Board of Allergy &amp; Immunology (ABA)</td>
<td>455</td>
</tr>
<tr>
<td>Amgen/AstraZeneca Pharmaceuticals, LP</td>
<td>701</td>
</tr>
<tr>
<td>Annals of Allergy, Asthma &amp; Immunology</td>
<td>917</td>
</tr>
<tr>
<td>* Aquestive Therapeutics, Inc.</td>
<td>655</td>
</tr>
<tr>
<td>* APL Pharmaceuticals, Inc.</td>
<td>641</td>
</tr>
<tr>
<td>* Aspire Allergy &amp; Sinus</td>
<td>322</td>
</tr>
<tr>
<td>AstraZeneca Pharmaceuticals, LP</td>
<td>410</td>
</tr>
<tr>
<td>Astra Therapeutics</td>
<td>544</td>
</tr>
<tr>
<td>* Bellus Health</td>
<td>911</td>
</tr>
<tr>
<td>BioCryst Pharmaceuticals, Inc.</td>
<td>310</td>
</tr>
<tr>
<td>Blueprint Medicines</td>
<td>648</td>
</tr>
<tr>
<td>Brevium</td>
<td>333</td>
</tr>
<tr>
<td>* Chemotechnique Diagnostics / Danner Laboratories Inc.</td>
<td>926</td>
</tr>
<tr>
<td>College Resource Center</td>
<td>815</td>
</tr>
<tr>
<td>coVita</td>
<td>543</td>
</tr>
<tr>
<td>* CoTeHealth</td>
<td>325</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>615</td>
</tr>
<tr>
<td>CVS Specialty</td>
<td>642</td>
</tr>
<tr>
<td>Cycle Pharmaceuticals</td>
<td>329</td>
</tr>
<tr>
<td>DBV Technologies</td>
<td>319</td>
</tr>
<tr>
<td>Elsevier</td>
<td>318</td>
</tr>
<tr>
<td>* EverInc</td>
<td>444</td>
</tr>
<tr>
<td>Fig (Food is Good)</td>
<td>447</td>
</tr>
<tr>
<td>Food Allergy &amp; Anaphylaxis Connection Team (FAACT)</td>
<td>320</td>
</tr>
<tr>
<td>Food Allergy Research and Education (FARE)</td>
<td>736</td>
</tr>
<tr>
<td>Genentech</td>
<td>619</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>300</td>
</tr>
<tr>
<td>Grifols USA, LLC</td>
<td>635</td>
</tr>
<tr>
<td>Hikma Specialty USA Inc.</td>
<td>440</td>
</tr>
<tr>
<td>HollisterStier Allergy</td>
<td>528</td>
</tr>
<tr>
<td>Horizon Therapeutics</td>
<td>210</td>
</tr>
<tr>
<td>Incyte Corp.</td>
<td>628</td>
</tr>
<tr>
<td>Incyte US Medical Affairs</td>
<td>436</td>
</tr>
<tr>
<td>* Infinity Bio, Inc.</td>
<td>550</td>
</tr>
<tr>
<td>* Intellia Therapeutics</td>
<td>730</td>
</tr>
<tr>
<td>* Ionis Pharmaceuticals</td>
<td>341</td>
</tr>
<tr>
<td>KabaFusion</td>
<td>554</td>
</tr>
<tr>
<td>Kaiser Permanente - Southern California Permanente Medical Group</td>
<td>546</td>
</tr>
<tr>
<td>Kallo</td>
<td>517</td>
</tr>
<tr>
<td>* Kadran Biopharma</td>
<td>833</td>
</tr>
<tr>
<td>Kruger Specialty Infusion</td>
<td>831</td>
</tr>
<tr>
<td>Lincoln Diagnostics, Inc.</td>
<td>529</td>
</tr>
<tr>
<td>Marshfield Clinic Health System</td>
<td>345</td>
</tr>
<tr>
<td>Medi Lazer</td>
<td>432</td>
</tr>
<tr>
<td>* Medical Practice Purchasing Group</td>
<td>913</td>
</tr>
<tr>
<td>MedicoCX</td>
<td>532</td>
</tr>
<tr>
<td>* MedTech International Group</td>
<td>629</td>
</tr>
<tr>
<td>MGC Diagnostics</td>
<td>335</td>
</tr>
<tr>
<td>Micro Direct, Inc.</td>
<td>732</td>
</tr>
<tr>
<td>Mission: Allergy, Inc.</td>
<td>719</td>
</tr>
<tr>
<td>ModMed</td>
<td>733</td>
</tr>
<tr>
<td>ModuleMD, LLC</td>
<td>631</td>
</tr>
<tr>
<td>Malekule</td>
<td>446</td>
</tr>
<tr>
<td>Morgan Scientific, Inc.</td>
<td>434</td>
</tr>
<tr>
<td>MotherToBaby Pregnancy Studies</td>
<td>449</td>
</tr>
<tr>
<td>National Eczema Association</td>
<td>431</td>
</tr>
<tr>
<td>National Jewish Health</td>
<td>330</td>
</tr>
<tr>
<td>NeilMed Pharmaceuticals, Inc.</td>
<td>638</td>
</tr>
<tr>
<td>Nestlé Health Science</td>
<td>552</td>
</tr>
<tr>
<td>* Neskin Medical</td>
<td>903</td>
</tr>
<tr>
<td>NIOX® (formerly Circassia Inc.)</td>
<td>907</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation</td>
<td>614</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals</td>
<td>351</td>
</tr>
<tr>
<td>Octapharma USA</td>
<td>542</td>
</tr>
<tr>
<td>* Panatex Inc.</td>
<td>555</td>
</tr>
<tr>
<td>Penn State Health Milton S. Hershey Medical Center</td>
<td>915</td>
</tr>
<tr>
<td>Pfizer Derm</td>
<td>713</td>
</tr>
<tr>
<td>Pfizer IGIV</td>
<td>811</td>
</tr>
<tr>
<td>Pharming Healthcare</td>
<td>723</td>
</tr>
<tr>
<td>PulmOne USA</td>
<td>422</td>
</tr>
<tr>
<td>Rabbit Air</td>
<td>323</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals/Sanoﬁ</td>
<td>501</td>
</tr>
<tr>
<td>Respir US</td>
<td>461</td>
</tr>
<tr>
<td>Sanford Health</td>
<td>338</td>
</tr>
<tr>
<td>SENTA Partners</td>
<td>334</td>
</tr>
<tr>
<td>SmartPractice</td>
<td>219</td>
</tr>
<tr>
<td>* Sobi, Inc.</td>
<td>214</td>
</tr>
<tr>
<td>* Southern ENT &amp; Allergy Conference</td>
<td>924</td>
</tr>
<tr>
<td>Staligenecea Greer</td>
<td>918</td>
</tr>
<tr>
<td>Takeda Pharmaceuticals</td>
<td>419</td>
</tr>
<tr>
<td>Teva Pharmaceuticals</td>
<td>326</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>901</td>
</tr>
<tr>
<td>Vancrream / Pharmaceutical Specialties, Inc.</td>
<td>728</td>
</tr>
<tr>
<td>* VETTED Dermilab</td>
<td>553</td>
</tr>
<tr>
<td>* Virant Diagnostics, Inc.</td>
<td>754</td>
</tr>
<tr>
<td>Vitalslograph, Inc.</td>
<td>216</td>
</tr>
<tr>
<td>* WikiAllergies LLC</td>
<td>327</td>
</tr>
<tr>
<td>* Wonder Spray, LLC</td>
<td>453</td>
</tr>
<tr>
<td>World Allergy Organization (WAO)</td>
<td>451</td>
</tr>
</tbody>
</table>

* First-time exhibitor

Map brought to you by ModMed, Booth 733
# Time for an Allergist campaign reaches millions

After achieving highly positive results in its first six months, the College’s award-winning “Time for an Allergist” campaign was extended for the 2023 fall allergy season. The campaign reached out to primary care providers and the public to encourage referrals to board certified and fellowship-trained allergists. The commercials have been viewed more than 3.2 million times, and the campaign has resulted in more than 40,000 “Find an Allergist” searches. View the campaign videos at TimeForAnAllergist.com. Just as important, explore our toolkit designed just for allergists with resources to market your practice to primary care practices and patients in your community.

Find the toolkit at college.acaai.org/time-for-an-allergist.

---

## Non-CME Corporate Forum
Sponsored by Blueprint Medicines

### AI vs AI: Diagnostic Dilemmas in Mast Cell Disorders

**Friday, November 10th, 6:45AM - 7:45AM PT**  
Anaheim Convention Center, Room 201CD  
Breakfast will be served.

This program is intended for U.S. healthcare professionals only.

Join Allergy and Immunology experts in mast cell disorders, with a focus on systemic mastocytosis (SM).

Questions related to disease state and diagnosis of SM will be assessed using ChatGPT vs the experts and the limitations of artificial intelligence.

**Matthew P. Giannetti, MD**  
Brigham and Women’s Hospital  
  
**Dareen Siri, MD**  
Midwest Allergy Sinus Asthma SC

Register at: www.tinyurl.com/BPM2023Symposium

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology. This program is sponsored by Blueprint Medicines and is not accredited for continuing medical education. Blueprint Medicines is committed to complying with all applicable laws and regulations. As such, Blueprint Medicines will disclose information related to meals or items of value provided to you. If there are regulations or policies that prohibit or restrict you from accepting meals, you are responsible for complying with them.

Blueprint Medicines and associated logo are trademarks of Blueprint Medicines Corporation. © 2023 Blueprint Medicines Corporation. 09/2023 US-BP-MED-NP-23030

---

## Coding and more

Plan to attend Annual Meeting sessions on billing/coding and government relations.

The Advocacy Council of ACAAI has you covered when it comes to coding and government relations. Stay current with coding changes!

Plan to attend the 2023 Allergy Coding Update (Friday, Nov. 10, 8:00 – 9:30 am, convention center room 213CD). Gary N. Gross, MD, FACAACI, will provide updates to effectively manage your revenue cycle.

This year the College’s House of Delegates Annual Town Hall Meeting is on Friday, Nov. 10, 4:30 – 6:00 pm, convention center room 210AB. It is titled The Future of Allergy – My Perspective and will include three 20-minute presentations addressing the strengths, weaknesses, opportunities and threats (SWOT) of:

- Making a practice more efficient.
- Offering ways to improve revenue streams.
- Fostering cooperation between community and academic allergists.
- Vision of your practice in the future.

Travis Miller, MD, FACAACI, will present his views as a solo allergy practitioner. Alan Baptist, MD, FACAACI, will present his viewpoints as an academician. Weily Soong, MD, FACAACI, will share his perspective as an allergist in a large, national allergy organization. Melinda Rathkopf, MD, MBA, FACAACI, will moderate the program. We hope to see you there!

Plan to attend Coding and Government Relations (Sunday, Nov. 12, 10:00 – 11:30 am, convention center room 210AB). This session will address relevant changes, modifications and implementation of CPT and ICD-10 coding for 2023 – 2024. Washington Consultant Matt Reiter will cover the national perspective on medicine and provide an update on the changing landscape on Capitol Hill as it relates to the current state of government.

While you’re at the meeting, don’t forget to stop by the College booth in the Exhibit Hall – booth 815. Participate in our advocacy grassroots activity and see how the College and the Advocacy Council are working for you!

A
North American Pediatric Allergy & Asthma Congress
Advances in Pediatric Allergy: Moving Towards Proactive Management
Las Vegas, Nevada

REGISTRATION IS OPEN!
For more information, please visit education.acaai.org/NAPAAC24 or scan the QR code below.

Presented by
American College of Allergy, Asthma & Immunology
&
Canadian Society of Allergy and Clinical Immunology
California-style fun

The Annual Meeting’s social events take advantage of Anaheim’s great weather and amp up competition among FITs. All meeting registrants are invited to attend.

Make a meaningful investment in allergy/immunology

The Annual Meeting is a great time to make a gift to The Allergists’ Foundation. Your support will allow us to fund projects under the Community Grant Program that aim to remove barriers to allergy care, improve patient health outcomes and ensure the well-being of our communities.

The Foundation awarded nearly $100,000 in community grants earlier this year.

Projects funded through the program use collaborative, community-based approaches to address important unmet needs. Our grantees will focus on gaining perspectives on unanswered questions in mild asthma, providing training in anaphylaxis management, using artificial intelligence to reduce administrative burdens, assessing prevalence of atopic diseases in underserved populations, studying poor indoor air quality and asthma, establishing school-based asthma management in rural settings, and testing new technology in food allergy management.

Our goal is to expand the reach of the Community Grant Program by funding another round of outstanding projects in 2024. We invite you to join us in this critical investment in our specialty by donating. Your gift can make all the difference toward empowering practicing allergists and ensuring richer, fuller lives for our patients!

To make a gift, text “allergists” to 50155, go to college.acaai.org/donate or stop by the College Resource Center (booth #815).

The Community Grant Program is possible through donations from members of the College and generous support by GSK.

Find the College Resource Center in the Exhibit Hall – booth 815.

Hours:
2:00 pm – 6:00 pm, Friday
9:00 am – 4:30 pm, Saturday
9:00 am – 1:30 pm, Sunday

President’s Welcome Reception

We’ve got a one-of-a-kind California experience planned for the President’s Welcome Reception on Friday, Nov. 10 from 6:00 to 7:30 pm at the Anaheim Convention Center’s outdoor Grand Plaza. Stroll the beautiful surroundings that feature a cascading water fountain, walking paths and palm trees. Join us for an evening of hors d’oeuvres, drinks, photo ops and camaraderie.

FIT Bowl

Who will be this year’s FIT Bowl champions? Teams of Fellows-in-Training compete for the trophy at Saturday evening’s FIT Bowl competition. Contestants are asked serious (and not so serious) questions by an expert panel. Who will answer correctly to win? It’s an exciting evening full of competition. Enjoy hors d’oeuvres and an open bar at this fast-paced, dynamic event at 5:45 pm on Saturday, Nov. 11, at the Hilton Anaheim Hotel.

How is the College working for you?

Explore the benefits of your College membership

The Exhibit Hall is the place to be when you’re not attending a workshop or symposium. Hundreds of company representatives are waiting to show you the latest products and services for your practice and patient care. It’s also the place to review the latest research, attend Product Theaters and attend the Job Fair. It’s also the place to review the latest research, attend Product Theaters and attend the Job Fair. And have some fun with the Passport Contest!

While you’re visiting the Exhibit Hall, be sure to visit the College Resource Center to hear more about your member benefits, the latest College programs and more! Not a member yet? The College Resource Center is a great place to learn about College membership.

• Stop by to learn more about tools and resources for practicing allergists.
• See what’s new on the College Learning Connection, your online home for professional development, and in the Practice Management Center, your online source for your practice needs.
• Learn about the important work of the Advocacy Council and the Allergists’ Foundation.
• Don’t forget the Passport Contest! See the mobile app to participate in this activity. Visit the participating booths and ask to scan their designated QR code, using the “Scan” button in the mobile app.

Once scanned, you will be taken back to the leaderboard and see your new score displayed. Participants with the most points collected will be entered into a drawing to win one of five prizes and will be notified by email. You do not need to be present to win. When the game has ended, you will no longer be able to scan QR codes and accumulate points. The contest will begin Friday, Nov. 10 at 2:00 pm and end Sunday, Nov. 12, at 1:30 pm. Win one of five $100 Amazon gift cards.
A Look Into the Future of Food Allergy Management
Putting Emerging Treatments Into Context

FRIDAY, NOVEMBER 10, 2023 | 8:00 – 10:00 PM PT
REGISTRATION AND MEAL: 8:00 PM | SYMPOSIUM: 8:30 PM
HILTON ANAHEIM HOTEL, 777 W CONVENTION WAY
ANAHEIM, CALIFORNIA | ROOM: CALIFORNIA BALLROOM SALON B (2ND FLOOR)

IN-PERSON

MODERATOR
David R. Stukus, MD
Professor of Clinical Pediatrics
Nationwide Children’s Hospital
The Ohio State University
College of Medicine
Columbus, Ohio

AGENDA
Welcome and Introduction
David R. Stukus, MD
Burden of Food Allergies
All Faculty
How Do We Manage Food Allergies Today?
All Faculty
Pathophysiology and Implications for Targeted Treatments
All Faculty
Emerging Therapies for Food Allergies
All Faculty
Concluding Remarks
David R. Stukus, MD

Meal offered

SPEAKERS
Rima Rachid, MD
Associate Professor of Pediatrics
Harvard Medical School
Director
Allergen Immunotherapy Program
Co-Director
Food Allergy Program
Principal Investigator
FARE Clinical Network
Discovery Center
Boston Children’s Hospital
Boston, Massachusetts

Matthew J. Greenhawt, MD
Professor of Pediatrics
Section of Allergy and Immunology
Children’s Hospital Colorado
Department of Pediatrics
University of Colorado
School of Medicine
Aurora, Colorado

For more information and to register, visit:
www.medscape.org/symposium/food-allergy-management

Supported by an independent grant from Genentech, Inc.
TEZSPIRE®
(tezepelumab-ekko) Subcutaneous Injection 210 mg

Aim Higher.

Visit TEZSPIREHCP.com